Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on November 18, 2013. The report discloses the granting of inducement stock options to recently hired executive officers, fulfilling obligations agreed upon during their hiring processes following the company's spin-off of Harvard Apparatus Regenerative Technology, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to the stock option grants:
- Exercise Price: $4.31 per share (based on the 10-day volume weighted average price preceding the grant).
- Total Options Granted: 800,000 options across four executives.
Material Changes
The material event reported is the formal grant of stock options to four new executives on November 18, 2013, which occurred on the eleventh trading day after the distribution date of the spin-off. The breakdown of grants is as follows:
- Jeffrey A. Duchemin (CEO): 500,000 options.
- Robert E. Gagnon (CFO): 150,000 options.
- Yong Sun (VP Strategic Marketing and Business Development): 100,000 options.
- Yoav Sibony (VP Global Sales): 50,000 options.
Guidance, Outlook, and Vesting Terms
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies beyond the specific terms of the compensation grants. Vesting schedules are defined as:
- CEO (Mr. Duchemin): Options fully vest three years from the date of grant.
- Other Executives: Options vest in four equal annual installments over four years from the date of grant.
Investor Verification Checklist
- Verify the current stock price relative to the $4.31 exercise price to assess the intrinsic value of the grants.
- Confirm the total number of authorized shares and the impact of these 800,000 new options on potential dilution.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K does not contain them.
- Monitor the vesting schedule to understand future compensation expense recognition.